Safety and tolerability of antiepileptic drugs in women with epilepsy (literature review and own data)

Women with epilepsy are at particular risk of developing side effects due to antiepileptic drugs (AED). Neuroendocrine disorders in women can be caused by both epilepsy itself and the therapy. This literature review aims to evaluate safety and tolerability of different AED in girls and women of reproductive age, incidence of neuroendocrine disorders associated with AED, and pregnancy outcomes in women with epi­lepsy. We also provide some own research results. We conducted a retrospective analysis of data for 345female patients aged between 15 and 40 years that were followed up at the Svt. Luka’s Institute of Child Neurology and Epilepsy between 2000 and 2018. We also performed a separate analysis of neuroendocrine disorders and pregnancy outcomes in these women. We found that 65 patients (18.8 %) developed pronounced neuroendocrine reproductive and cosmetic disorders (menstrual disorders, including dysmenorrhea, opsomenorrhea, amenorrhea, anovulatory cycles, and infertility; cosmetic neuroendocrine disorders, including obesity, hirsutism, and hair loss; adverse pregnancy outcomes), which significantly reduced the quality of life. Neuroendocrine disorders were observed in 55patients, whereas adverse pregnancy outcomes were registered in 10 (14.2 %) out of 70pregnancies.

1. Vlasov P.N., Karlov V.A., Petrukhin A.S. Epilepsy and pregnancy: current treatment strategy. Nevrologiya, neiropsikhiatriya, psikhoso- matika = Neurology, Neuropsychiatry, Psychosomatics 2013;(1):13—7. (In Russ.).

2. Vlasov P.N. Epilepsy in women: clinical, electrophysiological, hormonal, and therapeutic aspects. Summary of thesis ... of doctor of medical sci¬ences. Moscow, 2001. 48 p. (In Russ.).

3. Zhidkova I., Karlov V., Adamyan L. Epilepsy and female reproductive health. Clinical, pathogenetic, and therapeutic aspects. Palmarium Academic Publishing, 2012. 278 p. (In Russ.).

4. Zhidkova I.A. Effect of epilepsy and antiepileptic therapy on women’s reproductive health. Summary of thesis ...of candidate of medical sciences. Moscow, 2010. 153 p. (In Russ.).

5. Кarlov V.A., Vlasov P.N., Kushlinskiy N.E. et al. Epilepsy and pregnancy. In: Epilepsy in children and adult men and women. Moscow: Meditsina, 2010. Pp. 543-562. (In Russ.).

6. Karlov V.A. Treatment of epilepsy. In: Epilepsy in children and adult men and women. Moscow: Meditsina, 2010. P. 631-659. (In Russ.).

7. Mukhin K.Yu., Glukhova L.Yu., Bobylova M.Yu. et al. Epileptic syndromes. Diagnosis and treatment. 4th edn. Moscow: “Binom” LLC, 2018. 608 p. (In Russ.).

8. Mukhin K.Yu., Pylaeva O.A. Safety and tolerability of antiepileptic drugs in women with epilepsy (the data of Svt. Luka’s Institute of Child Neurology and Epilepsy). Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology 2015;10(1):16-23. (In Russ.).

9. Mukhin K.Yu., Pylaeva O.A. Juvenile myoclonic epilepsy: emphasis on the use of topiramate (literature review and own data). Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology 2017;12(2): 8-20. (In Russ.).

10. Pylaeva O.A., Mukhin K.Yu., Morozov D.V. Treatment of epilepsy in girls and women. Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology 2015;10(1):24—39. (In Russ.)].

11. Pylaeva O.A., Mukhin K.Yu., Petrukhin A.S. Side effects of antiepileptic medication. Moscow: Granat, 2016. 232 p. (In Russ.).

12. Pediatric epileptology: guide for clinicians. Ed. by A.S. Petrukhin. Moscow: Meditsina, 2000. 624 p. (In Russ.).

13. Battino D., Tomson T. Management of epilepsy during pregnancy. Drugs 2007;67(18):2727—46. PMID: 26187231. DOI: 10.1212/WNL.0000000000001840.

14. Ben-Menachem E. Weight issues for peo¬ple with epilepsy — a review. Epilepsia 2007;48(suppl 9):42-5. PMID: 18047602. DOI: 10.nn/j.1528-1167.2007.01402.x.

15. Bromley R.L., Weston J., Marson A.G. Ma¬ternal use of antiepileptic agents during preg¬nancy and major congenital malformations in children. JAMA 2017;318(17):1700—1. DOI: 10.1001/jama.2017.14485.

16. Christensen J., Gronborg T.K., Sorensen M.J. et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013;309(16):1696—703. DOI: 10.1001/jama.2013.2270.

17. Qiijek N.P., Kama^ak T., Serin M. et al. The effects of valproate and topiramate use on serum insulin, leptin, neuropeptide Y and ghrelin levels in epileptic children. Seizure 2018;58:90-5. PMID: 29679911. DOI: 10.1016/j.seizure.2018.03.013.

18. Crettenand M., Rossetti A.O., Buclin T., Winterfeld U. Use of antiepileptic drugs during breastfeeding: What do we tell the mother? Nervenarzt 2018;89(8):913-921. PMID: 29487964. DOI: 10.1007/s00115- 018-0496-2.

19. Demir E., Aysun S. Weight gain associated with valproate in childhood. Pediatr Neu¬rol 2000;22(5):361—4. PMID: 10913727.

20. Dupont S. Specific aspects of the manage¬ment of women with epilepsy. Presse Med 2018;47(3):251 —60. DOI: 10.1016/j. lpm.2018.01.020.

21. Eisenschenk S. Treatment with oxcarbaze- pine during pregnancy. Neurologist 2006;12(5):249—54. PMID: 16990737. DOI: 10.1097/01. nrl.0000215743.02301.17.

22. Espinosa A.R., Gavvala J., Bellinski I. et al. Counseling by epileptologists affects contraceptive choices of women with epi¬lepsy. Epilepsy Behav 2016;65:1—6. DOI: 10.1016/j.yebeh.2016.08.021.

23. Galappatthy P., Liyanage C.K., Lucas M.N. et al. Obstetric outcomes and effects on babies born to women treated for epilepsy during pregnancy in a resource limited set¬ting: a comparative cohort study. BMC Pregnancy Childbirth 2018;18(1):230. DOI: 10.1186/s12884-018-1857-3.

24. Gelisse P., Juntas-Morales R., Genton P. et al. Dramatic weight loss with levetirace- tam. Epilepsia 2008;49(2):308—15. PMID: 17825078. DOI: 10.1111/j.1528-1167.2007.01273.x.

25. Genton P., Bauer J., Duncan S. et al. On the association between valproat and poly¬cystic ovary syndrome. Epilepsia 2001;42(3):295—304. PMID: 11442143.

26. Genton P. Valproic acid, adverse effects. In: Antiepileptic Drugs. Philadelphia: Lippincott Williams & Wilkins, 2002. Pp. 837—851.

27. Harden C.L. Antiepileptic drug teratogen- esis: what are the risks for congenital mal¬formations and adverse cognitive out¬comes? Int Rev Neurobiol 2008;83: 205—13. PMID: 18929083. DOI: 10.1016/ S0074-7742(08)00011-1.

28. Harden C.L. Pregnancy and epilepsy. Se-min Neurol 2007;27(5):453—9. PMID: 17940924. DOI: 10.1055/s-2007-991125.

29. Harden C.L., Meador K.J., Pennell P.B. et al. Management issues for women with epilepsy — focus on pregnancy (an evi¬dence-based review). II: Teratogenesis and perinatal outcomes. Epilepsia 2009;50(5):1237—46. PMID: 19507301.

30. Harden C.L., Meador K.J., Pennell P.B. et al. Practice parameter update: manage-ment issues for women with epilepsy — fo¬cus on pregnancy (an evidence-based re¬view): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009;73(2):133—41. PMID: 19398681. DOI: 10.1212/WNL.0b013e3181a6b312.

31. Harden C.L., Pennell P.B., Koppel B.S. et al. Management issues for women with epilepsy — focus on pregnancy (an evi-dence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Re¬port of the Quality Standards Subcommit¬tee and Therapeutics and Technology As¬sessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009;50(5):1247—55.

32. NICE guidance. Available at: https://www. nice.org.uk/guidance.

33. Isojarvi J.I., Tapanainen J.S. Valproate, hyperandrogenism, and polycystic ovaries: a report of 3 cases. Neurol 2000;57(7):1064—8. PMID: 10891991.

34. Johannessen S.I., Helde G., Brodtkorb E. Levetiracetam in serum and in breastmilk at birth and during lactation. Epilepsia 2005;46:775—7. PMID: 15857447. DOI: 10.1111/j.1528-1167.2005.54804.x.

35. Kuhnz W., Kock S., Helge H. et al. Primi¬done and phenobarbital during lactation period in epileptic women: total and free drug serum levels in the nursed infants and their effects on neonatal behavior. Dev Pharmacol Ther 1988;11:147—54. PMID: 3383727.

36. Kuwagata M., Ogawa T., Shioda S., Na- gata T. Observation of fetal brain in a rat valproate-induced autism model: a deve¬lopmental neurotoxicity study. Int J Dev Neurosci 2009;27(4):399—405. PMID: 19460635. DOI: 10.1016/j. ijdevneu.2009.01.006.

37. Meischenguiser R., D’Giano C.H., Fer-raro S.M. Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy Behav 2004;5(2):163—7.

38. Mikkonen K., Vaniopaa K., Pakarinen A.J. et al. Long-term reproducyive endocrine health in yong women with epilepsy during puberty. Neurology 2004;62:445—50. PMID: 14872028.

39. Montouris G. Safety of the newer antiepi¬leptic drug oxcarbazepine during pregnan¬cy. Curr Med Res Opin 2005;21(5): 693—701. PMID: 15969868. DOI: 10.1185/030079905X43640.

40. Morrell M.J., Guidice L., Flynn K.L. et al. Predictors of ovulatiry failure in women with epilepsy. Ann Neurol 2002;52: 704—11. PMID: 12447923. DOI: 10.1002/ ana.10391.

41. Morrell M.J., Montouris G.D. Reproduc-tive disturbances in patients with epilepsy. Cleveland Clinic J Med 2004;71(suppl 2): 19—24. PMID: 15379296.

42. Novak G.P., Maytal J., Alshansky A. et al. Risk of excessive weight gain in epileptic children treated with valproate. J Child Neurol 1999;14:490—5. PMID: 10456757. DOI: 10.1177/088307389901400802.

43. Ornoy A. Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol 2009;28(1):1 —10. PMID: 1.9490988. DOI: 10.1016/j.repro- tox.2009.02.014.

44. Oxcarbazepine. Drugs and Lactation Da-tabase (LactMed). Available at: https:// www.ncbi.nlm.nih.gov/books/ NBK501243/.

45. Panayiotopoulos C.P. A clinical guide to epi¬leptic syndromes and their treatment. 2nd edn. Springer, 2010. Pp. 45—49; 325—335.

46. Panayiotopoulos C.P. Principles of Thera¬py in the Epilepsies.In: Clinical Guide to Epileptic Syndromes and their Treatment. Berlin: Springer, 2007. Pp. 155—84.

47. Petersen I., Collings S.-L., McCrea R.L. et al. Antiepileptic drugs prescribed in pregnancy and prevalence of major con¬genital malformations: comparative preva¬lence studies. Clin Epidemiol 2017;9: 95—103.

48. Pickrell W.O., Lacey A.S., Thomas R.H. et al. Weight change associated with anti-epileptic drugs. J Neurol Neurosurg Psy-chiatry 2013;84:796—9. PMID: 23236017. DOI: 10.1136/jnnp-2012-303688.

49. Reife R., Pledger G., Wu S.C. Topiramate as add-on therapy: pooled analysis of random¬ized controlled trials in adults. Epilepsia 2000;41(suppl 1):S66—71. PMID: 10768304.

50. Rubinchik-Stern M., Shmuel M., Bar J. et al. Adverse placental effects of valproic acid: Studies in perfused human placentas. Epilepsia 2018;59(5):993—1003. DOI: 10.1111/epi.14078. 

51. Sabers A., Tomson T. Managing antiepi-leptic drugs during pregnancy and lacta-tion. Curr Opin Neurol 2009;22(2): 157-61. PMID: 19532039. DOI: 10.1097/ WCO.0b013e32832923d7.

52. Sima I.P., Page B.P. Management of epi-lepsy during pregnancy: an update. Ther Adv Neurol Disord 2016;9(2):118—29. DOI: 10.1177/1756285615623934.

53. Tassinarri C.A., Michelucci R., Chauvel P. et al. Double-blind placebo-controlled tri¬al of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:763-8.

54. Titze K., Koch S., Helge H. et al. Prena¬tal and family risks of children born to mothers with epilepsy: effects on cogni-tive development. Dev Med Child Neu¬rol 2008;50(2):117—22. PMID: 18177411. DOI: 10.1111/j.1469-8749.2007.02020.x.

55. Tomson T., Battino D., Bonizzoni E. et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10(7):609—17.

56. Tomson T., Palm R., Kallen K. et al. Phar¬macokinetics of levetiracetam during preg¬nancy, delivery, in the neonatal period and lactation. Epilepsia 2007;48:1111-6. PMID: 17381438. DOI: 10.1111/j.1528-1167.2007.01032.x.

57. Vajda FJ., O’Brien T.J, Lander C.M. et al. The teratogenicity of the newer antiepileptic drugs — an update. Acta Neurol Scand 2014;130(4):234— 8. DOI: 10.1111/ane.12280.

58. Wang H., Bos J.H., de Jong-van den Berg L.T. Co-prescription of antiepileptic drugs and contraceptives. Contraception 2012;85(1):28—31. PMID: 22067799. DOI: 10.1016/j.contracep- tion.2011.04.017.

59. Westin A.A., Reimers A., Helde G. et al. Serum concentration/dose ratio of leveti- racetam before, during and after pregnan¬cy. Seizure 2008;17:192—8.

60. Weston J., Bromley R., Jackson C.F. et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev 2016;11:CD010224. PMID: 27819746. DOI: 10.1002/14651858.CD010224.pub2.

61. Yang Y., Wang X. Sexual dysfunction related to antiepileptic drugs in patients with epilep¬sy. Expert Opin Drug Saf 2016;15(1):31—42. DOI: 10.1517/14740338.2016.1112376.